A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

October 23, 2023

Study Completion Date

October 23, 2023

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

Standard of Care

Standard of Care

GENETIC

JCAR017

JCAR017

Trial Locations (54)

3010

Local Institution - 700, Bern

9000

Local Institution - 350, Ghent

10065

Local Institution - 117, New York

10126

Local Institution - 502, Torino

13125

Local Institution - 451, Berlin

13273

Local Institution - 400, Marseille

14263

Local Institution - 111, Buffalo

15232

Local Institution - 123, Pittsburgh

20089

Local Institution - 501, Rozzano (MI)

20246

Local Institution - 452, Hamburg

23298

Local Institution - 114, Richmond

28041

Local Institution - 601, Madrid

28204

Local Institution - 125, Charlotte

30322

Local Institution - 108, Atlanta

30342

Local Institution - 107, Atlanta

32224

Mayo Clinic - Jacksonville, Jacksonville

33612

Local Institution - 126, Tampa

48109

Local Institution - 120, Ann Arbor

48149

Local Institution - 454, Münster

48201

Local Institution - 119, Detroit

50937

Local Institution - 450, Cologne

55455

Local Institution - 112, Minneapolis

59037

Local Institution - 401, Lille

60153

Loyola University Medical Center Cardinal Bernardin Cancer Center, Maywood

60611

Local Institution - 122, Chicago

68198

Local Institution - 100, Omaha

69495

Local Institution - 403, Pierre-Bénite

73104

Local Institution - 127, Oklahoma City

75246

Local Institution - 109, Dallas

77030

Local Institution - 124, Houston

80045

Local Institution - 106, Aurora

81377

Local Institution - 453, München

85258

Local Institution - 129, Scottsdale

85259

Local Institution - 116, Scottsdale

94143

Local Institution - 115, San Francisco

94805

Local Institution - 402, Villejuif

97239

Local Institution - 101, Portland

02114

Local Institution - 102, Boston

02215

Local Institution - 104, Boston

55905-0001

Local Institution - 103, Rochester

07601

Local Institution - 121, Hackensack

98109-4417

Local Institution - 110, Seattle

00029

Local Institution - UNK 25, Helsinki

01307

Local Institution - 455, Dresden

00161

Local Institution - 500, Rome

545-8586

Local Institution - 203, Osaka

104-0045

Local Institution - 200, Chuo-ku

105-8470

Local Institution - 201, Minato-ku

113-8677

Local Institution - 202, Bunkyō City

3075 EA

Local Institution - 550, Rotterdam

08036

Local Institution - 600, Barcelona

SE-141 86

Local Institution - 650, Stockholm

SO16 6YD

Local Institution - 751, Southampton

WC1E 6AG

Local Institution - 750, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT03575351 - A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas | Biotech Hunter | Biotech Hunter